Literature DB >> 9582033

Antiretroviral therapy for HIV infection: promises and problems.

P A Volberding1, S G Deeks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9582033     DOI： 10.1001/jama.279.17.1343

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  12 in total

1.  Factors associated with the time elapsed between the initial detection of HIV-1 antibodies and a diagnosis of AIDS among patients followed in Lyons University Hospitals. CISIH Collaborators.

Authors:  P Vanhems; D Baratin; R Allard; E Marceillac; F Biron; L Cotte; T Saint-Marc
Journal:  Sex Transm Infect       Date:  1999-12       Impact factor: 3.519

2.  Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study.

Authors:  Mehdi Nouraie; Sergei Nekhai; Victor R Gordeuk
Journal:  Sex Transm Infect       Date:  2012-05-24       Impact factor: 3.519

3.  Helping the urban poor stay with antiretroviral HIV drug therapy.

Authors:  J D Bamberger; J Unick; P Klein; M Fraser; M Chesney; M H Katz
Journal:  Am J Public Health       Date:  2000-05       Impact factor: 9.308

4.  Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.

Authors:  K E Zhang; E Wu; A K Patick; B Kerr; M Zorbas; A Lankford; T Kobayashi; Y Maeda; B Shetty; S Webber
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses.

Authors:  V Blazevic; S Jankelevich; S M Steinberg; F Jacobsen; R Yarchoan; G M Shearer
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

6.  Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Authors:  David A Price; George Scullard; Annette Oxenius; Ruth Braganza; Simon A Beddows; Shamim Kazmi; John R Clarke; Gabriele E Johnson; Jonathan N Weber; Rodney E Phillips
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques.

Authors:  Adriano Boasso; Monica Vaccari; Dietmar Fuchs; Andrew W Hardy; Wen-Po Tsai; Elzbieta Tryniszewska; Gene M Shearer; Genoveffa Franchini
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

8.  Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor.

Authors:  Emilio Ortiz-Riaño; Nhi Ngo; Stefanie Devito; Dirk Eggink; Joshua Munger; Megan L Shaw; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

Review 9.  Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.

Authors:  E A Berger; B Moss; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

10.  Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.

Authors:  Teresa H Evering; Saurabh Mehandru; Paul Racz; Klara Tenner-Racz; Michael A Poles; Amir Figueroa; Hiroshi Mohri; Martin Markowitz
Journal:  PLoS Pathog       Date:  2012-02-02       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.